Depletion of G9a protein abolishes the transcriptional response to oestrogen and inhibits cell proliferation and transformation, suggesting that G9a is a potential therapeutic target for the treatment of ER-positive human breast cancers. This evidence concerns the gene EHMT2 and breast carcinoma.